Abstract
We analyzed the incidence and risk factors for chronic graft-versus-host disease (GVHD) in 265 children undergoing allogeneic stem cell transplantation (SCT) who survived longer than 3 months post SCT. Patients transplanted from HLA-mismatched related donors and matched unrelated donors were included. Fifty-five patients developed chronic GVHD between 1 and 25 months after SCT, and the 5-year cumulative incidence of chronic GVHD was 22%. By multivariate analysis, acute GVHD (P = 0.004), malignant disease (P = 0.004), recipient age (⩾10 years) (P = 0.01) and a female donor to male recipient (P = 0.035) were significant risk factors for chronic GVHD. When acute GVHD was excluded from the multivariate analysis, malignant disease (P = 0.002) and older recipient age (P = 0.007) were identified. The incidence of chronic GVHD in this childhood study was lower than that observed in adults, and recipient age was an important factor in childhood SCT. The high incidence associated with malignant disease may be affected by changes in GVHD prophylaxis in order to ensure graft-versus-tumor effects. Bone Marrow Transplantation (2001) 27, 727–730.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Atkinson K . Chronic graft-versus-host disease Bone Marrow Transplant 1990 5: 69–82
Ringden O, Paulin T, Lonnqvist B et al. An analysis of factors predisposing to chronic graft-versus-host disease Exp Hematol 1985 13: 1062–1067
Storb R, Prentice RL, Sullivan KM et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings Ann Intern Med 1983 98: 461–466
Niederwieser D, Pepe M, Storb R et al. Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia Bone Marrow Transplant 1989 4: 151–156
Atkinson K, Horowitz MM, Gale RP et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation Blood 1990 75: 2459–2464
Ochs LA, Miller WJ, Filipovich AH et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation Bone Marrow Transplant 1994 13: 455–460
Carlens S, Ringden O, Remberger M et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis Bone Marrow Transplant 1998 22: 755–761
Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man, a long-term clinicopathologic study of 20 seattle patients Am J Med 1980 69: 204–217
Atkinson K, Horowitz MM, Gale RP et al. Consensus among bone marow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease Bone Marrow Transplant 1989 4: 247–254
Locatelli F, Uderzo C, Dini G et al. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A Bone Marrow Transplant 1993 12: 627–633
Eisner MD, August CS . Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation Bone Marrow Transplant 1995 15: 663–668
Weiden PL, Sullivan KM, Fiournoy N et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation New Engl J Med 1981 304: 1529–1533
Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA identical siblings as treatment of acute and chronic leukemia Blood 1989 73: 1720–1728
Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation Blood 1991 77: 649–653
Smigel K . When the side effect helps the treatment: graft-versus-tumor J Natl Cancer Inst 1993 85: 855–856
Eibi B, Schwaighofer H, Nachbaur D et al. Evidence for graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer Blood 1996 88: 1501–1508
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kondo, M., Kojima, S., Horibe, K. et al. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children. Bone Marrow Transplant 27, 727–730 (2001). https://doi.org/10.1038/sj.bmt.1702868
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702868
Keywords
This article is cited by
-
Chronic liver graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients during tapering or after stopping calcineurin inhibitors
International Journal of Hematology (2021)
-
Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia
Frontiers of Medicine (2019)
-
Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria
Bone Marrow Transplantation (2012)
-
Innovative approaches to treat steroid-resistant or steroid refractory GVHD
Bone Marrow Transplantation (2008)
-
Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease
International Journal of Hematology (2008)